Table 1.

General characteristics of study population and correlation between AR expression and clinicopathological factors

Characteristics	n (%)	AR positivity	p value
Age (n = 116)
≤ 35 years	20 (17.2)	15 (75.0)	0.06
> 35 years	96 (82.8)	50 (52.1)
Relation with ER, PR and HER2/neu status
ER+	54 (46.6)	39 (72.2)	< 0.001
ER-	62 (53.4)	26 (41.9)
PR+	46 (39.7)	34 (73.9)	< 0.002
PR-	70 (60.3)	31 (44.3)
HER2+	58 (50.0)	35 (60.3)	0.349
HER2-	58 (50.0)	30 (51.7)
Relation with breast cancer subtypes (in all ages) (n = 116)
Luminal A	27 (23.3)	21 (77.8)	0.003
Luminal B	30 (25.9)	19 (63.3)
HER2/neu enriched	29 (25.0)	16 (55.1)
Triple negative	30 (25.8)	9 (30)
Relation with breast cancer subtypes (in age ≤ 35 years) (n = 20)
Luminal A	8 (40.0)	7 (87.5)	0.099
Luminal B	5 (25.0)	5 (100.0)
HER2/neu enriched	5 (25.0)	2 (40.0)
Triple negative	2 (10.0)	1 (50.0)
Relation with breast cancer subtypes (in age > 35 years) (n = 96)
Luminal A	19 (19.8)	14 (73.6)	0.016
Luminal B	25 (26.0)	14 (56.0)
HER2/neu enriched	24 (25.0)	14 (58.3)
Triple negative	28 (29.2)	8 (28.6)
Overall stage (n = 116)
II	33 (28.5)	23 (69.7)	0.034
III	80 (68.9)	42 (52.5)
IV	3 (2.6)	0 (0)
Tumor size (n = 116)
T2	26 (22.4)	17 (65.4)	0.059
T3	22 (18.9)	16 (72.7)
T4	68 (58.7)	32 (47.1)
Nodal stage (n = 116)
N0	33 (28.4)	24 (72.7)	0.042
N1	57 (49.1)	31 (54.3)
N2	21 (18.1)	7 (33.3)
N3	5 (4.4)	3 (60)
Response to NACT (n = 72)
Progressive disease	7 (9.7)	2 (28.6)	0.218
Stable disease	6 (8.3)	1 (16.7)
Partial response	47 (65.3)	26 (55.3)
Complete response	12 (16.7)	6 (50.0)

AR = androgen receptor, ER = estrogen receptor, PR = progesterone receptor, NACT = neoadjuvant chemotherapy.